araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Assessing Quality of Life of Patients With Prostate Cancer

Summary: RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate and long-term effects of the treatment on these patients.
  PURPOSE: Clinical trial to study the effectiveness of two questionnaires in assessing quality of life of patients who have prostate cancer.

Detailed description: OBJECTIVES:
  -  Assess the scale structure, psychometric validity, and reliability of quality of life measurements using the EORTC QLQ-C30 and the prostate cancer-specific QLQ-PR25 questionnaires in patients with stage I-IV prostate cancer.
  OUTLINE: This is a multicenter study. Patients are stratified according to stage of disease (local or locally advanced disease vs metastatic disease).
  Patients complete EORTC QLQ-C30 and prostate cancer-specific QLQ-PR25 questionnaires before therapy and at 3 months after the start of therapy. Patients in stratum II also complete questionnaires at 6 months after the start of therapy.
  PROJECTED ACCRUAL: A total of 375 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically confirmed prostate cancer
  -  Stratum I:
  -  Clinically localized primary prostate cancer
  -  T1-T3, G1-G3, N0, M0
  -  Plan to undergo a radical prostatectomy OR
  -  Local or locally advanced primary prostate cancer
  -  T1-T4, G1-G3, N0, M0
  -  Plan to undergo radiotherapy with curative intent
  -  Stratum II:
  -  Metastatic prostate cancer
  -  T1-T4, G1-G3, N1, M0-M1 OR
  -  T1-T4, G1-G3, N0-1, M1
  -  Plan to receive hormonal treatment
  -  No anti-androgen monotherapy
  -  No cerebral metastases
  PATIENT CHARACTERISTICS:
  Age:
  -  Any age
  Performance status:
  -  Not specified
  Life expectancy:
  -  Not specified
  Hematopoietic:
  -  Not specified
  Hepatic:
  -  Not specified
  Renal:
  -  Not specified
  Other:
  -  Mentally fit to complete a questionnaire
  -  Literate in the language of the questionnaires
  -  No psychological, familial, sociological, or geographical condition that would preclude compliance
  -  No other concurrent malignancy except basal cell skin cancer
  -  No concurrent participation in other quality of life investigations that would preclude study participation
  PRIOR CONCURRENT THERAPY:
  Biologic therapy:
  -  Not specified
  Chemotherapy:
  -  Not specified
  Endocrine therapy:
  -  See Disease Characteristics
  -  No prior neoadjuvant hormonal treatment
  -  Planned adjuvant hormonal therapy (orchiectomy, luteinizing hormone-releasing hormone analogue, or maximal androgen blockade) is allowed for patients in stratum I
  Radiotherapy:
  -  See Disease Characteristics
  -  No interstitial radiotherapy
  -  More than 2 years since prior radiotherapy (stratum II)
  Surgery:
  -  See Disease Characteristics
  -  More than 2 years since prior prostatectomy (stratum II)
  Other:
  -  No prior treatment for prostate carcinoma

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Reiki/Energy Healing in Prostate Cancer

Summary: The purpose of this study is to determine whether Reiki energy healing affects anxiety and disease progression in patients with localized prostate cancer who are candidates for radical prostatectomy.

Detailed description: 120 newly diagnosed prostate cancer patients will be randomized to one of 3 groups: Reiki, another touch therapy, or guided imagery. Subjects in the Reiki and touch therapy groups have 8 sessions in the 4 weeks prior to their medical intervention. Those in the imagery group have one session prior to their medical intervention.

Eligibility: Inclusion criteria:
  -  Newly diagnosed with prostate cancer
  -  Scheduled for radial prostatectomy, external beam radiation, brachytherapy, or a combination of these
  Exclusion criteria:
  -  Already involved in energy healing treatments
  -  Any patient whose medical intervention could not wait the 4-weeks for intervention for medical reasons
  -  Any patient who gets neo-adjuvant therapy or any herbal product that could affect PSA

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases

Summary: RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Strontium-89 may relieve bone pain caused by prostate cancer. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Combining doxorubicin and strontium-89 with celecoxib may kill more tumor cells.
  PURPOSE: This randomized phase II trial is studying celecoxib together with doxorubicin and strontium-89 to see how well they work compared to doxorubicin and strontium-89 alone in treating patients with progressive androgen-independent prostate cancer and bone metastases.

Detailed description: OBJECTIVES:
  -  Compare time to prostate-specific antigen progression in patients with progressive androgen-independent prostate cancer and bone metastases treated with doxorubicin and strontium chloride Sr 89 with or without celecoxib.
  OUTLINE: This is a randomized study. Patients are stratified according to extent of bone metastases on bone scan (> 20 lesions vs ≤ 20 lesions) and quality of response (i.e., decline of the prostate-specific antigen from baseline) to prior induction chemotherapy (≥ 80% vs < 80%). Patients are randomized to 1 of 2 treatment arms.
  -  Arm I: Patients receive doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 and strontium chloride Sr 89 IV on day 1. Patients also receive oral celecoxib twice daily in the absence of disease progression.
  -  Arm II: Patients receive doxorubicin and strontium chloride Sr 89 as in arm I.
  PROJECTED ACCRUAL: A total of 70 patients (35 per treatment arm) will be accrued for this study within 18 months.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of androgen-independent prostate cancer
  -  Osteoblastic metastases
  -  No predominant visceral metastases
  -  Progressive disease after response to prior induction chemotherapy (prostate-specific antigen decline of at least 50% from baseline after 16 weeks of treatment)
  -  No symptomatic lymphadenopathy (i.e., scrotal or pedal edema)
  PATIENT CHARACTERISTICS:
  Age
  -  Any age
  Performance status
  -  Not specified
  Life expectancy
  -  Not specified
  Hematopoietic
  -  Not specified
  Hepatic
  -  Not specified
  Renal
  -  Not specified
  Other
  -  Adequate physiologic reserves
  PRIOR CONCURRENT THERAPY:
  Biologic therapy
  -  Not specified
  Chemotherapy
  -  See Disease Characteristics
  Endocrine therapy
  -  Not specified
  Radiotherapy
  -  No prior radionuclide therapy
  Surgery
  -  Not specified
  Other
  -  No more than 3 prior cytotoxic treatments
  -  More than 6 months since prior celecoxib or rofecoxib

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer

Summary: RATIONALE: New imaging procedures such as CT-on-rails™ may improve the ability to pinpoint the location of the tumor and decrease radiation therapy damage to healthy tissue.
  PURPOSE: This phase I/II trial is studying how well computed tomography (CT) scans using CT-on-rails™ work in pinpointing the location of the tumor in patients with prostate cancer.

Detailed description: OBJECTIVES:
  Primary
  -  Validate the software for CT-on-rails™ by comparing prostate target localization via daily ultrasound vs computed tomography (CT) in patients undergoing radiotherapy for prostate cancer.
  Secondary
  -  Determine the potential benefit of using fiducials in the prostate of patients undergoing daily CT scans and/or ultrasounds for localization.
  -  Determine the intra- and inter-radiation treatment setup and target position uncertainties, in terms of isocenter coordinates in space, using both the ultrasound and CT scans compared to the coordinates of the isocenter determined at simulation, in these patients.
  OUTLINE: This is a pilot study.
  -  Phase I: Patients undergo computed tomography (CT) using CT-on-rails™ twice weekly. Patients undergo BAT™ ultrasound daily for prostate localization. Patients undergo concurrent daily radiotherapy off study after imaging. After radiotherapy treatment is complete, patients continue to undergo scanning using CT-on-rails™ twice weekly.
  -  Phase II: Patients undergo local anesthesia and surgical insertion of gold fiducial markers into the prostate. After 1 week, patients undergo a daily CT scan using CT-on-rails™ and bi-weekly BAT™ ultrasound. Patients undergo daily radiotherapy off study after imaging. After radiotherapy treatment is complete, patients continue to undergo scanning using CT-on-rails™ twice weekly.
  PROJECTED ACCRUAL: A total of 40 patients (20 per study phase) will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Diagnosis of definitive prostate cancer
  -  Radiotherapy planned as treatment
  PATIENT CHARACTERISTICS:
  Age
  -  Any age
  Performance status
  -  Not specified
  Life expectancy
  -  Not specified
  Hematopoietic
  -  Not specified
  Hepatic
  -  Not specified
  Renal
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  Biologic therapy
  -  Not specified
  Chemotherapy
  -  Not specified
  Endocrine therapy
  -  Not specified
  Radiotherapy
  -  See Disease Characteristics
  Surgery
  -  Not specified

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Summary: The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.


Eligibility: Inclusion Criteria:
  -  Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate
  -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
  -  Detectable metastases
  -  Any Gleason score
  -  ECOG performance status 0-2
  Exclusion Criteria:
  -  Prior treatment with chemotherapy
  -  Prior Immunotherapy
  -  Prior treatment with gene therapy
  -  Significant cancer related pain

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Summary: This phase I trial is studying the side effects and best dose of docetaxel when given with radiation therapy and hormone therapy in patients with locally advanced prostate cancer.

Detailed description: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Docetaxel may also make tumor cells more sensitive to radiation therapy. Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, or bicalutamide, may stop the adrenal glands from making androgens. Giving chemotherapy with radiation therapy and hormone therapy may kill more tumor cells.

Eligibility: Inclusion Criteria:
  1. Histologically confirmed adenocarcinoma of the prostate with one of the prognostic factors specified in the protocol. No pelvic lymph node disease that would necessitate pelvic radiotherapy. No radiologic evidence of metastatic disease on bone scan or on CT scan or MRI of the abdomen or pelvis
  2. No prior radiation therapy, chemotherapy, immunotherapy or alternative therapy for prostate cancer. Greater than 4 weeks since any major surgery.
  3. Performance status 0-2
  4. Must meet criteria for acceptable lab values as outlined in the protocol.
  5. Peripheral neuropathy must be greater than or equal to 1
  6. Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
  Exclusion Criteria:
  1. No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with Polysorbate 80

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Summary: This randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.

Detailed description: Radiation therapy plus six months of hormone therapy is one standard way of treating men with high-risk prostate cancer. In this study, we want to see whether or not adding the chemotherapy drug docetaxel (Taxotere)will make this treatment more effective. Docetaxel has shown a benefit in median survival when given to men who have become resistant to hormonal therapy and in men who have metastatic prostate cancer (spread to other areas of the body).

Eligibility: Inclusion Criteria:
  -  Biopsy proven prostate cancer
  -  Clinical Tumor Category T1b, T1c, T2a and PSA greater than (>) 10 or Gleason score equal or greater than 4+3=7 or PSA velocity > 2.0 ng/ml per year and also eligible patients with tumor category T2c, T3a, T3b, or T4 as per 2002 AJCC guidelines. Any minor tertiary grade of Gleason 5; Biopsy Proven or Radiographic (erMRI Seminal Vesicle Invasion); Gleason = or > 3+4=7 with 50% or more cores positive
  -  Negative bone scan
  -  Lymph node assessment by CT or MR
  -  Adequate hematologic function (Blood Counts)
  -  Adequate liver functions (blood tests)
  -  ECOG performance Status 0 or 1
  -  Peripheral neuropathy must be =< grade 1
  -  PSA obtained within 3 months of entry
  Exclusion Criteria:
  -  Prior history of malignancy that are < 5 years except for cancers found to be "in-situ" and would not likely impact a patient's life expectancy with appropriate medical management.
  -  Prior pelvic radiation therapy
  -  Prior hormonal therapy (up to 4 weeks prior to enrollment allowed)
  -  Individuals unable to tolerate lying still 5 - 10 minutes
  -  Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 90.

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

Summary: This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen [PSA] levels) and who were about to start a new line of chemotherapy. Blood was drawn prior to the patient receiving chemotherapy and then monthly thereafter for up to 18 months or until disease progression, whichever occurred first. The blood was tested to find circulating tumor cells (CTC) and to count them. The circulating tumor cell levels were studied in relation to the patient's overall survival. Serum was also collected for PSA testing, and additional blood samples were drawn to test for circulating endothelial cells and RNA was isolated for future gene expression testing.


Eligibility: Inclusion Criteria:
  -  Age > or = 18 years
  -  Pathological diagnosis of adenocarcinoma of the prostate
  -  First or later line of chemotherapy
  -  Serum testosterone < 50ng/mL
  -  ECOG 0-2
  -  Serum PSA > or = 5ng/mL
  -  PSA progression (2 rises above a reference value)
  -  Bone scan within 60 days of enrollment
  -  Computed tomography (CT) scan
  -  If measurable disease, bone scans every 6-8 months
  Exclusion Criteria:
  -  Systemic radiation
  -  Prior history of other carcinoma within the last 5 years, except non-melanoma skin cancer
  -  Brain metastases

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Study Evaluating the Correlation Between C-11 Acetate Uptake and Retention as Measured by PET and FAS in Prostate Cancer

Summary: The purpose of this study is to understand if a new type of radiology test called positron emission tomography (PET) with carbon 11 acetate will help us to understand which cancers produce more of a protein called fatty acid synthase (FAS).

Detailed description: -  Within 4 weeks of the patient's scheduled surgery they will undergo a C11 acetate PET scan. This scan will be performed at the Massachusetts General Hospital's Nuclear Medicine Department and involves an intravenous injection of acetate with a radioactive tracer followed by a PET scan. The scan will determine how well the tumor is taking up the acetate.
  -  Patients will also undergo a CT scan of the pelvis at the same time as the PET scan.
  -  After surgery, the removed tumor will have additional testing that will look at different factors that may tell us how aggressive the tumor is and how much FAS is within the tumor. FAS seems to be produced in higher amounts by prostate cancer cells than normal cells. We will then try to determine if the results of the C11 acetate PET scan can tell us how much FAS is produced by prostate cancer cells.

Eligibility: Inclusion Criteria:
  -  Histologically documented prostate cancer
  -  Planned radical prostatectomy
  -  > 50% cores positive for prostate cancer from prostate biopsy or a palpable prostate nodule
  -  Older than 18 years of age
  Exclusion Criteria:
  -  Inability to lay on a scanner for 60 minutes

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

Summary: The purpose of this study is to evaluate clinical and laboratory safety in patients receiving 4 different doses of GVAX® Prostate Cancer Vaccine in order to determine a maximum tolerated dose.


Eligibility: Inclusion Criteria:
  -  Diagnosis of adenocarcinoma of the prostate
  -  Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
  -  Detectable metastases
  -  ECOG performance status of 0 or 1
  Exclusion Criteria:
  -  Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
  -  Significant cancer related pain
  -  Prior gene therapy, chemotherapy, or immunotherapy

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Family History in Prostate Cancer Patients in Taiwan

Summary: To investigate the prevalence of family history in prostate cancer patients in Taiwan and evaluate the association of variation of diseases and family history

Detailed description: We retrospectively reviewed the medical charts of prostate cancer patients at NTUH from 1978 to 2002. The initial presentations, systemic diseases, smoking habits, clinical stages, Gleason scores, pathological stages, treatments, and outcome were recorded. Post-hoc questionnaires were completed with OPD visits, admission visits, telephone interviews and mails. The questionnaires included the family histories of prostate cancer, colon cancer, breast cancer, hepatoma and so on. If patients is passed away, the first degree relatives will fill the vacant position. The prevalence of family histories of prostate cancers in these patients was determined. The associations of family histories and clinical presentations were analyzed. Besides, the characteristics of patients with and without responses were discussed.

Eligibility: Inclusion Criteria:
  -  Prostate cancer patients who were recorded at National Taiwan University Hospital from 1977 to 2002.
  Exclusion Criteria:
  -  Patients or their family who refused our contact or were unable to be contacted

Relevance to patient case: not relevant
Patient case: 81-year-old male with Prostate cancer. Genetic variant: PTEN Inactivating. Other conditions: Hypertension, Depression.

Clinical trial: Exisulind Prior to Radical Prostatectomy

Summary: This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily for the 4 weeks prior to radical prostatectomy. Participants will be followed for total of 2 months from the time of starting study drug.


Eligibility: Males 40 years of age and older with prostate cancer who are scheduled to undergo surgical removal of the prostate at Mayo Clinic Rochester, Mayo Clinic Jacksonville, or Mayo Clinic Arizona may be eligible for this protocol.

Relevance to patient case: not relevant